Abstract RF2-07: Nodal disease burden in patients with clinically node-positive breast cancer undergoing tailored axillary surgery with or without axillary dissection in the neoadjuvant and upfront surgery setting: pre-planned TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

View at publisher
Authors: W. P. Weber, Christoph Tausch, S. Hayoz, Zoltán Mátrai, Grigorios Xepapadakis, Colin Simonson, Vesna Bjelic-Radisic, G-T Lam, Giacomo Montagna, M.I. Gnant, LH Rosenberger, Eelco de Bree
+38 more Rok Satler, M. Fehr, C. Leo, Loïc Lelièvre, S. Bucher, Seraina Margaretha Schmid, Robert Exner, Klaus Reisenberger, U. Beckmann, Simone E. Muenst, Guido Henke, Daniel R. Zwahlen, Thomas Ruhstaller, Karin Ribi, C. Urban, Angelena Crown, J. E. Lee, J-F. Boileau, A. D. Williams, Jonghan Yu, Maggie Lee DiNome, Antigoni Poultsidi, E. Gonzales, S. M. Wong, A. Schulz, Matthew D. Nealeigh, S. G. Ahn, Astrid Botty van den Bruele, B.J. Chae, A. Mueller, Daniela Hagen, J. M. Ryu, Ákos Sávolt, C. Kurzeder, J. Heil, Daniel Egle, Martin Heidinger, Michael Knauer
Cited by: 0

Abstract

Abstract Introduction: The safety of omitting axillary dissection (ALND) in patients with clinically node-positive breast cancer (cN+ BC) may depend on the nodal disease burden left behind in the axilla. This study aimed to evaluate nodal disease volume, quantify nodal understaging without ALND, and identify factors associated with additional nodal disease at ALND in these patients. Methods: The international phase-III TAXIS trial (NCT03513614) randomized patients with cN+ stage II-III BC to ALND or axillary radiotherapy (ART) following tailored axillary surgery (TAS). Nodal disease was detected by imaging or palpation at initial diagnosis. TAS removed sentinel, biopsied, and palpably suspicious nodes. Patients had upfront surgery or residual nodal disease after neoadjuvant chemotherapy (NACT). 1500 patients were randomized from 08/2018 to 08/2025. Results: Of 1418 patients with available data, 712 (50.2%) underwent ALND. Nodal disease was detected by imaging in 735 patients (51.8%), and by palpation in 683 (48.2%). Clinical nodal stage was cN1 in 1232 (86.9%) and cN2/3 in 186 (13.1%). Tumors were HR-positive and HER2-negative in 1140 patients (80.4%), HER2-positive in 160 (11.3%), and triple negative in 96 (6.8%). 552 patients (38.9%) underwent NACT. TAS removed a median of 5 nodes (interquartile range [IQR] 3-7), 2 (IQR 1-4) of which were positive. After TAS, ALND removed a median of 11 additional nodes (IQR 8-16), one (IQR 0-4) of which was positive. Among 712 patients undergoing ALND, additional positive nodes after TAS were removed in 430 (60.4%), AJCC pN upstaging occurred in 226 (31.7%), and 336 (47.2%) had (y)pN2/3 stage. Nodal burden by use of NACT is shown in the table. On multivariable logistic regression the number of positive nodes on TAS was associated with higher odds of having additional positive nodes on ALND in the NACT (odds ratio [OR] 1.57, 95% confidence interval [CI] 1.21-2.03, p

Fields of Study & Subjects

Breast Cancer Treatment Studies Breast Lesions and Carcinomas MRI in cancer diagnosis

Publication details

Journal / source
Clinical Cancer Research
Volume
32
Issue
4_Supplement
Pages
RF2–07
Publication date
17 February 2026
Language
EN